Lipoprotein apheresis in Austria – Reduction of cardiovascular events by regular lipoprotein apheresis treatment
| Autor: | Theresa Berent, Robert Berent, Helmut Sinzinger, Kurt Derfler |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Hyperlipoproteinemias medicine.medical_specialty Time Factors Psychological intervention Familial hypercholesterolemia 030204 cardiovascular system & hematology Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Internal Medicine Humans Medicine 030212 general & internal medicine Aged Retrospective Studies biology business.industry Vascular disease Incidence Incidence (epidemiology) General Medicine Lipoprotein(a) Middle Aged medicine.disease Treatment Outcome Apheresis Cardiovascular Diseases Austria Blood Component Removal biology.protein Female Cardiology and Cardiovascular Medicine business Mace Lipoprotein |
| Zdroj: | Atherosclerosis Supplements. 40:8-11 |
| ISSN: | 1567-5688 |
| DOI: | 10.1016/j.atherosclerosissup.2019.08.025 |
| Popis: | Background In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Germany. Regular LP-apheresis aims to decrease apolipoprotein B-rich lipoproteins and to reduce cardiovascular events. In this analysis we present the current situation of LP-apheresis in Austria and we evaluated the cardiovascular event rate 2 years before versus 2 years after starting LP-apheresis. Methods A retrospective analysis of 30 patients (19 men and 11 women) was performed at Athos Institute, Vienna, Austria. The study period included two years prior versus two years after the beginning of LP-apheresis. Cardiovascular events and interventions were defined as regarding the coronary (MACE) or the non-coronary (peripheral, cerebral or renal) vascular system. Results The first cardiovascular event before treatment initiation occurred at a mean age of 48.4 years (range 34–73), treatment was started at a mean age of 55.6 years (range 34–73). The mean rate of incidence of cardiovascular events per patient per 2 years before beginning of LP-apheresis (y-2 and y-1) versus 2 years during treatment (y+1 and y+2) was reduced by 77.78% (1.50 versus 0.33 events/patient/2 years, p = 0.003). Conclusions The significant reduction in MACE and vascular disease during regular LP-apheresis at weekly intervals is consistent with data from the literature. Difficulties arise in comparing such studies due to different definition of events or interventions and different study durations. However, LP-apheresis is an efficient treatment option and causes significantly prolonged event-free survival for patients at risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect